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Abstract: Background. Invasive fungal infections are a major cause
of morbidity and mortality among solid organ transplant (SOT) and
hematopoietic cell transplant (HCT) recipients, but few data have
been reported on the epidemiology of endemic fungal infections in
these populations.
Methods. Fifteen institutions belonging to the Transplant-Associated
Infection Surveillance Network prospectively enrolled SOT and HCT
recipients with histoplasmosis, blastomycosis, or coccidioidomycosis
occurring between March 2001 and March 2006.
Results. A total of 70 patients (64 SOT recipients and 6 HCT
recipients) had infection with an endemic mycosis, including 52 with
histoplasmosis, 9 with blastomycosis, and 9 with coccidioidomycosis.
The 12-month cumulative incidence rate among SOT recipients for
histoplasmosis was 0.102%. Occurrence of infection was bimodal; 28
(40%) infections occurred in the first 6 months post transplantation,
and 24 (34%) occurred between 2 and 11 years post transplantation.
Three patients were documented to have acquired infection from the
donor organ. Seven SOT recipients with histoplasmosis and 3 with
coccidioidomycosis died (16%); no HCT recipient died.
Conclusions. This 5-year multicenter prospective surveillance study
found that endemic mycoses occur uncommonly in SOT and HCT
recipients, and that the period at risk extends for years after
transplantation.
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Histoplasma capsulatum, Blastomyces dermatitidis, and
Coccidioides species are endemic fungi in the United
States, andeachgenus is uniquely associatedwithhuman
disease within a relatively restricted geographic location.
Histoplasmosis occurs predominantly in the Ohio and
Mississippi River valleys; blastomycosis in the upper
Midwest, the Great Lakes region, and south central
states; and coccidioidomycosis in the southwest. The
endemic fungi often cause infection following inhalation
of conidia that exist primarily in soil. Invasive infections
are seen in immunosuppressed patients, particularly
those with human immunodeficiency virus/acquired
immunodeficiency syndrome (AIDS) or those receiving
tumor necrosis factor antagonists. Recipients of solid
organ transplant (SOT) or hematopoietic cell transplant
(HCT) appear to acquire infection caused by endemic
fungi less commonly than reported for those immuno-
suppressive conditions noted above (1). However, sur-
veillance for endemic fungal infections among transplant
recipients has not been performed systematically and
thus, the incidence and distribution of endemic fungal
infections among the transplant population is not known.
The Transplant-Associated Infection Surveillance Net-
work (TRANSNET) was established in 2001 to perform
prospective surveillance for invasive fungal infections
(IFIs) among all transplant recipients at 23 selected
centers throughout the United States between 2001 and
2006. The goals were to establish the burden of IFIs in
the transplant population, to define the current
approach to diagnosis and treatment, and to describe
the outcomes of these infections. Overall incidence
rates for IFIs have been reported among the SOT and
HCT populations enrolled in TRANSNET (2–4). In this
report, we focus on endemic fungal infections that
occurred in this cohort. We sought to better define the
timing of occurrence of infection post transplantation,
the clinical characteristics of the population, treatment,
and outcomes of histoplasmosis, blastomycosis, and
coccidioidomycosis in SOT and HCT recipients.
Methods
Study sites
Fifteen of the 23 TRANSNET sites provided prospective
surveillance data for endemic mycoses in SOT and HCT
recipients from March 2001 through March 2006. The
Surveillance Cohort comprised SOT and HCT recipients
who developed an infection with an endemic mycosis
during this period, regardless of when or where their
transplant occurred. The Incidence Cohort comprised
patients who underwent transplantation during the
surveillance period at 1 of the 15 study sites. Data
collected on all patients in the Incidence Cohort included
demographics (age, gender, race/ethnicity), type of
transplant, date of last follow-up, and outcome.
Definitions and case identification
Endemic fungal infections were identified prospectively
through review of monthly logs of transplant recipients,
culture data, serodiagnostic studies, and histopathology
results, and by regular contact with transplant physi-
cians and coordinators. Case data included demograph-
ics, date and type of transplant, infection type and site,
method of diagnosis, co-morbid conditions, past or
current infections, recent immunosuppressive treat-
ment, rejection episodes, graft-versus-host disease
(GVHD), antifungal treatment, and status 3 months
after initial diagnosis of infection. Among those patients
who died, the investigator determined whether death
was likely due to the endemic mycosis or to another
cause, and these determinations were reviewed by the
Data Review Committee.
The diagnosis of histoplasmosis, blastomycosis, or
coccidioidomycosis was established by growth of the
organism in culture, a positive Histoplasma serum or
urine antigen test in a patient who had a compatible
clinical illness, or histopathologic identification of the
typical yeast forms of H. capsulatum and B. dermatit-
idis or spherules typical of Coccidioides species. Cases
were categorized as pulmonary infection when the only
organ noted to be involved was the lungs; the presence
of antigenemia or antigenuria did not change this
categorization. Disseminated infection was manifested
by evidence of non-pulmonary involvement by histopa-
thology or culture, radiographic imaging, or antigen-
emia or antigenuria with no pulmonary infiltrates on
imaging; only 2 patients had antigenemia or antigenuria
alone as the only criterion for disseminated infection.
The category of pulmonary infection with dissemination
designated patients in whom infection was documented
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in both lungs and an extra-pulmonary site, irrespective
of antigenemia or antigenuria. All cases were reviewed
by the Data Review Committee to determine individual
case validity.
Data analysis
Data entry and verification were performed by the
Biostatistical Unit at the University of Alabama at
Birmingham. Final data cleaning and data analysis were
performed at the Centers for Disease Control and
Prevention in Atlanta. The descriptive analysis of
endemic fungal infections reflects infections occurring
during the study period, independent of when or where
the transplant occurred (Surveillance Cohort).
Data from the Incidence Cohort were pooled to
calculate cumulative incidence curves. Cumulative
incidence estimates for transplant-related infections
within the first 12 months after transplant were
estimated, accounting for the competing risks of
infection-free death, re-transplantation, and return to
chronic dialysis for renal transplant recipients. Because
only a few patients had blastomycosis and coccidioido-
mycosis and very few HCT recipients were reported
with an endemic fungal infection, the cumulative
incidence was calculated only for histoplasmosis among
SOT recipients.
Results
Demographic characteristics (Surveillance Cohort)
A total of 70 endemic fungal infections were reported in
the Surveillance Cohort between 2001 and 2006. The
mean age at diagnosis was 52 years (range 12–68), 64%
were male, and the majority was Caucasian (Table 1).
Of these 70 cases, 64 (91%) occurred in SOT recipients;
this includes 48 cases of histoplasmosis, 9 of blastomy-
cosis, and 7 of coccidioidomycosis. Kidney transplant
recipients, including 7 who received a kidney-pancreas
transplant, accounted for 40 of these 64 cases (62.5%),
and liver transplant recipients accounted for an
Demographic characteristics of hematopoietic cell and solid organ transplant (SOT) recipients who developed endemic fungal infections
Number (%)
Characteristic Blastomycosis (N = 9) Coccidioidomycosis (N = 9) Histoplasmosis (N = 52) Total (N = 70)
Hematopoietic cell 0 2 (22) 4 (8) 6 (9)
Autologous 0 1 (11) 3 (6) 4 (6)
Allogeneic 0 1 (11) 1 (2) 2 (3)
Solid organ1 9 (100) 7 (78) 48 (92) 64 (91)
Heart 1 (11) 0 (0) 2 (4) 3 (4)
Kidney 5 (56) 4 (57) 24 (50) 33 (47)
Kidney-pancreas 0 (0) 0 (0) 7 (15) 7 (10)
Liver 2 (22) 3 (43) 12 (25) 17 (24)
Lung 0 0 3 (6) 3 (4)
Pancreas 1 (11) 0 0 1 (2)
Age, median (range) 57 (38–68) 55 (24–64) 51 (12–68) 52 (12–68)
Female 3 (33) 1 (11) 21 (40) 25 (36)
Male 6 (67) 8 (89) 31 (60) 45 (64)
Caucasian 8 (89) 7 (78) 43 (83) 58 (83)
African American 0 1 (11) 7 (13) 8 (11)
Other2 1 (11) 1 (11) 2 (4) 4 (6)
1Total SOT performed in the Incidence Cohort: kidney = 8672; kidney-pancreas = 746; liver = 4468; lung = 1195; pancreas = 464;
heart = 1165; small bowel = 95.
2Hispanic (2), Native American (1), Asian Pacific Islander (1).
Table 1
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additional 24% of cases (Table 1). The distribution of
infections by transplant type reflects the frequency of
the types of organs transplanted.
HCT recipients accounted for only 9% of cases of
endemic fungal infections. Six infections (4 histoplas-
mosis and 2 coccidioidomycosis) occurred in HCT
recipients. Four patients (2 with multiple myeloma, 1
with leukemia, and 1 with medulloblastoma) had each
received an autologous HCT, and 2 patients (1 each
with lymphoma and leukemia) had received an alloge-
neic HCT.
Geographic distribution of infections with endemic
mycoses
The distribution of cases from the 15 reporting centers is
shown in Figure 1. Seven cases of histoplasmosis
reported from Iowa were also included in a previous
report (5). Notably, 1 case of histoplasmosis and 6 cases
of coccidioidomycosis were reported from centers
located outside of the areas considered endemic for
these fungi. The patient who had histoplasmosis and 3 of
the patients who developed coccidioidomycosis were
known to have previously resided in or visited areas
known to be endemic for these fungi. Two other patients
from outside the endemic area appear to have acquired
coccidioidomycosis as a result of transmission from
transplanted organs, both of which came from the same
donor, whohad a prior history of coccidioidomycosis (6).
Rate of infection with endemic mycoses (Incidence
Cohort)
A total of 36 endemic fungal infections occurred in
patients who had received their transplant during the
study period (Incidence Cohort). Three infections, all
Fig. 1. Geographic distribution of cases of histoplasmosis, blastomycosis, and coccidioidomycosis reported from 15 transplant centers in the
TRANSNET network.
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histoplasmosis, occurred among 16,200 patients (0.02%)
who had received an HCT between March 2001 and
September 2005. Among the 16,806 patients who had
received an SOT in the same time period, 33 (0.2%)
developed an endemic mycosis. Among these 33
patients, 23 developed infection caused by H. capsula-
tum, 6 by Coccidioides species, and 4 by B. dermatitidis.
The 12-month cumulative incidence rate among SOT
recipients for histoplasmosis, the most common infec-
tion, was 0.102% (Fig. 2).
Time to infection post transplantation
For all 70 patients, the median time from transplanta-
tion to diagnosis of an endemic fungal infection was
274 days (range 15–3371) for HCT recipients and
343 days (range 0–4195) for SOT recipients. Figure 3
shows a box and whisker graph with the time to
infection for each organism. Twenty-eight patients
(40%) developed infection within 6 months post trans-
plantation; of the remaining 42 patients, 18 developed
infection within 2 years post transplantation and 24
patients experienced infection between 2 and 11 years
post transplantation.
One HCT recipient, who received an autologous
HCT, was diagnosed with disseminated histoplasmosis
at day 15 post transplant, but the others developed an
endemic fungal infection from 60 days to 9 years after
receiving a HCT.
Among 7 SOT recipients who developed infection
within 30 days of transplantation, 3 definitely were
thought to have acquired the organism via the trans-
planted organ. Histological evidence of existing Coccid-
ioides infection was found post mortem in the donor of a
liver and a kidney that were transplanted into 2 separate
recipients, neither of whom had ever visited the
endemic area. Both died of disseminated coccidioido-
mycosis within 3 weeks of transplantation (6). The third
patient, in whom a biopsy of the donor liver found
typical yeast forms of H. capsulatum, was begun imme-
diately on therapy and never developed symptomatic
infection. One other patient possibly acquired histoplas-
mosis from a donor kidney; this patient did not live in an
endemic area and was found to have disseminated
histoplasmosis 30 days after receiving an unrelated
donor kidney; unfortunately, no further data were
available regarding the donor. The remaining 3 patients
(1 liver transplant recipient and 2 kidney transplant
recipients) lived in the endemic area and had isolated
pulmonary infection without involvement of the trans-
planted organ; no further donor data were available.
Fig. 2. The 12-month cumulative incidence rate for histoplasmosis
among solid ogan transplant recipients in the Incidence Cohort.
Fig. 3. Box and whisker graph indicating time in years to the
diagnosis of an endemic mycosis among SOT and HCT recipients in
the Surveillance Cohort. The box represents the interquartile range
(25–75%). The total number of infections occurring ≤2 years post
transplantation is listed in the left-hand column, and the total number
of infections occurring >2 years post transplantation is listed in the
right-hand column. The median time to the diagnosis of each
infection is indicated by the dark vertical line within the box, and
the thin vertical lines indicate the range. SOT, solid organ transplant;
HCT, hematopoietic cell transplant; IFI, invasive fungal infection.
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Underlying conditions
All patients had underlying illnesses that required
transplantation, and many had other co-existing ill-
nesses (Table 2). All patients who received an SOT had
received immunosuppressive medications, predomi-
nantly calcineurin inhibitors, mycophenolate, and cor-
ticosteroids, at the time of transplantation, and most
remained on immunosuppressive medications at the
time of infection. A total of 19 of the 64 SOT patients
had experienced an episode of rejection at some time
after transplantation, but only 5 patients had an episode
of rejection with 6 weeks of the diagnosis of an
endemic mycosis.
Only 3 patients, all of whom developed histoplasmo-
sis and all of whom had received an autologous HCT,
were not on immunosuppressive agents when they
developed infection. The 2 patients who had an alloge-
neic HCT had GVHD and were being treated with
corticosteroids (>20 mg prednisone equivalent daily)
when they developed pulmonary histoplasmosis.
Prophylaxis with systemic antifungal agents was used
uncommonly. Two patients had received fluconazole
and another had received itraconazole prior to devel-
opment of coccidioidomycosis; another patient had
received fluconazole prior to the development of
histoplasmosis.
Concomitant infections
Concomitant infections were uncommon in transplant
recipients who developed an endemic mycosis. Her-
pesvirus infections, primarily cytomegalovirus infec-
tions, were the most frequent concomitant infections
noted within 30 days of the diagnosis of an endemic
mycosis (Table 3). Five patients had another IFI (3 had
candidemia and 1 each had invasive aspergillosis and
Alternaria sinusitis) concomitant with or within 30 days
of the diagnosis of infection with an endemic mycosis.
Organ involvement
Pulmonary involvement was common; however, it was
the sole manifestation of infection in only 25 patients
(36%) (Table 4). In the other 45 patients (64%), dissem-
ination had occurred and was present along with
pulmonary infection in 24 (34%). Dissemination was
seen in 71% of the 52 patients who had histoplasmosis,
Co-morbid conditions and immunosuppressive medications present within 30 days before the diagnosis of an endemic fungal infection in
hematopoietic cell and solid organ transplant recipients
Number (%)
Co-morbid condition/drug Blastomycosis (N = 9) Coccidioidomycosis (N = 9) Histoplasmosis (N = 52)
Diabetes mellitus 6 (67) 0 14 (27)
Malnutrition 5 (56) 0 3 (6)
Chronic lung disease 3 (33) 0 3 (6)
Congestive heart failure 2 (22) 0 2 (4)
Chronic kidney disease 3 (33) 3 (33) 19 (37)
Hepatic insufficiency 1 (11) 0 7 (13)
Rheumatologic disease 0 0 2 (4)
Rejection episode1 1 (11) 1 (11) 3 (6)
Immunosuppressive drugs
Corticosteroids2 9 (100) 8 (89) 45 (87)
Calcineurin inhibitors 8 (89) 7 (78) 39 (75)
Mycophenolate 6 (67) 7 (78) 27 (52)
Sirolimus 0 0 5 (10)
Azathioprine 0 0 1 (2)
1Within 6 weeks of the diagnosis of an endemic mycosis.
2Equivalent of ≥20 mg prednisone daily (methylprednisolone, dexamethasone, prednisone).
Table 2
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and in 5 (56%) of the 9 patients who had coccidioidomy-
cosis. Three (50%) of the 6 patients who had blastomy-
cosis had disseminated infection: numerous skin lesions
in 2 and central nervous system plus pulmonary infec-
tion in 1.
The time from transplantation to infection was not
related to dissemination. Patients with infection within
6 months of transplantation (19/28, 68%) were no more
likely to have disseminated infection than those who
developed disease >6 months post transplant (26/42,
62%).
Sites of dissemination that yielded the organism on
culture or histopathology, including those obtained at
autopsy, in patients with histoplasmosis were bone
marrow (in 8), liver (in 7), gastrointestinal tract (in 6),
kidney (in 3), spleen (in 2), skin (in 2), and knee,
thyroid, and lymph node (in 1 each).
Diagnosis
The diagnosis of fungal infection was made before
death in 67 patients, and only made at autopsy for 3
patients: 2 with donor-derived coccidioidomycosis, and
1 with histoplasmosis. Among those who had a diag-
nosis made before death, the most useful diagnostic
tests for all 3 endemic mycoses appeared to be culture
of sputum, bronchoalveolar lavage fluid, or lung biopsy
samples (Table 5). Histopathologic examination of lung
tissue identified the organism in 33% of cases of
blastomycosis and in 29% of cases of coccidioidomyco-
sis, but cytological examination of bronchoalveloar
lavage fluid was more useful for H. capsulatum (20%
of cases). Blood cultures proved useful only for
histoplasmosis; >50% of patients had H. capsulatum
isolated from blood.
Co-infections within 30 days of diagnosis of an endemic fungal infection in hematopoietic cell and solid organ transplant recipients
Number (%)
Co-infections Blastomycosis (N = 9) Coccidioidomycosis (N = 9) Histoplasmosis (N = 52) Total (N = 70)
Cytomegalovirus (CMV) 4 (44) 1 (11) 7 (13) 12 (17)
CMV antigenemia 2 (22) 0 4 (8) 6 (9)
CMV disease 2 (22) 1 (11) 3 (6) 6 (9)
Herpes simplex 0 0 1 (2) 1 (2)
Varicella zoster 1 (11) 0 0 1 (2)
Bloodstream infections
Gram-positive cocci 1 (11) 0 5 (10) 6 (9)
Gram-negative bacilli 0 0 4 (8) 4 (8)
Candida species 1 (11) 0 2 (4) 3 (4)
Invasive mold infections 2 (22) 0 0 2 (3)
Table 3
Type of infection with endemic mycoses among hematopoietic cell and solid organ transplant recipients
Number (%)
Site of infection Blastomycosis (N = 9) Coccidioidomycosis (N = 9) Histoplasmosis (N = 52) Total (N = 70)
Pulmonary alone 6 (67) 4 (44) 15 (29) 25 (36)
Pulmonary with dissemination 1 (11) 3 (33) 20 (38) 24 (34)
Disseminated 2 (22) 2 (22) 17 (33) 21 (30)
Table 4
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Among patients with histoplasmosis who underwent
Histoplasma antigen testing, results were positive in 29
from urine and in 13 patients from serum. Unfortu-
nately, data on the total number of patients who had
antigen testing performed were not reported. Only 2
patients with disseminated histoplasmosis had only a
positive antigen test without a positive culture or
histopathologic demonstration of tissue invasion. At
the time of this study, the Blastomyces antigen test was
not readily available. Antibody studies were rarely
obtained and were positive in only 3 patients with
histoplasmosis and in 3 with coccidioidomycosis.
Treatment
Three patients, 2 of whom had coccidioidomycosis and
1 who had histoplasmosis, were not treated with
antifungal agents because the diagnosis was made only
at autopsy. For the remaining 67 patients, initial
treatment was primarily with a lipid formulation of
amphotericin B (AmB) (Table 6). Of the 43 patients
who were treated with AmB at some point, 39 (91%)
received a lipid formulation of AmB. Only 4 patients, all
of whom had histoplasmosis, received AmB deoxy-
cholate. Seven patients received an AmB formulation
Diagnostic tests used to establish the pre-mortem diagnosis of endemic fungal infections in hematopoietic cell and solid organ transplant recipients
Number (%)*
Diagnostic test Blastomycosis (N = 9) Coccidioidomycosis (N = 7) Histoplasmosis (N = 51)
Positive culture
Blood 0 0 27 (53)
BAL/sputum 5 (56) 3 (43) 18 (35)
Lung 1 (11) 2 (29) 4 (8)
Skin 0 0 3 (6)
Bone marrow 0 0 4 (8)
Liver 0 0 1 (2)
Urine 0 0 2 (4)
Lymph node 0 0 1 (2)
Pleural fluid 0 0 1 (2)
Synovial fluid 0 1 (14) 1 (2)
Histopathology
Lung 3 (33) 2 (29) 5 (10)
Skin 2 (22) 1 (14) 1 (2)
Bone marrow 0 0 4 (8)
Liver 0 0 4 (8)
Kidney 0 0 1 (2)
Bowel 0 0 3 (6)
Esophagus 0 0 1 (2)
Cytology
BAL 1 (11) 1 (14) 10 (20)
Serology
Antigen, serum 0 0 13 (25)
Antigen, urine 0 0 29 (57)
Antibody, CF or ID 0 3 (43) 3 (6)
*Patients often had >1 positive diagnostic test.
BAL, bronchoalveolar lavage; CF, complement fixation; ID, immunodiffusion.
Table 5
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only, and 5 of these 7 patients died from 3 to 19 days
after the antifungal agent was started. Most other
patients, who were given AmB initially, were transi-
tioned to oral azole therapy, usually itraconazole, at a
mean of 17 days.
For patients deemed to have less severe disease, half
of whom had disseminated infection, therapy consisted
of an azole agent alone, primarily itraconazole. How-
ever, patients who had blastomycosis were treated
more frequently with voriconazole than with itracona-
zole. Fluconazole was rarely used to treat histoplasmo-
sis or blastomycosis, but this agent was used for 3 of
the 9 patients who had coccidioidomycosis.
Outcomes
At 3 months after an endemic fungal infection was
diagnosed, no deaths occurred among the 6 patients
who had received an HCT, and 10 deaths occurred
among the 64 (16%) SOT recipients. Among these 64
patients, death was thought likely to be a result of the
fungal infection in 7 (11%). Three of the 7 (43%) SOT
recipients who had coccidioidomycosis died; 2 of these
patients died of disseminated coccidioidomycosis that
was derived from the donor kidney and liver, and the
third patient died of bacterial pneumonia.
Seven of the 48 (15%) SOT recipients who developed
histoplasmosis died within 3 months of diagnosis, and 5
of these deaths were attributed to disseminated histo-
plasmosis. For those 5 patients, including 1 in whom
the diagnosis was made only at autopsy, death occurred
within 3–19 days after they presented with symptoms
of histoplasmosis. No deaths occurred at 3 months
among the 9 SOT recipients who had blastomycosis,
but 2 patients who had severe pulmonary blastomyco-
sis with acute respiratory distress syndrome were left
with chronic respiratory insufficiency. Mortality was
not different for patients who developed infection
within the first 6 months after transplantation (5/28,
18%) and those whose infection occurred >6 months
after transplantation (5/42, 12%, P = 0.72).
Discussion
Endemic mycoses are an uncommon cause of IFI in
SOT and HCT recipients. The strong associations noted
with Candida species infections in the immediate post-
transplant period and with opportunistic mold infec-
tions in patients with GVHD or rejection were not
apparent for infection with the endemic mycoses (2, 3).
Among SOT recipients in the Incidence Cohort, 33
(0.2%) developed an endemic mycosis during the
Treatment of endemic mycoses in hematopoietic cell and solid organ transplant recipients
Number (%)
Antifungal agent Blastomycosis (N = 9) Coccidioidomycosis (N = 9) Histoplasmosis (N = 52)
AmB, then Itra 2 (22) 0 26 (50)
AmB, then Vori 1 (11) 0 0
AmB + azole1 2 (22) 0 1 (2)
AmB 0 2 (22) 5 (10)
Itra 0 0 10 (19)
Vori 3 (33) 1 (11) 1 (2)
Flu 0 2 (22) 1 (2)
Azoles2 1 (11) 1 (11) 4 (8)
Azole, then AmB3 0 1 (11) 3 (6)
None4 0 2 (22) 1 (2)
1Blastomycosis: AmB + vori (in 2); Histoplasmosis: AmB + Flu (in 1).
2Blastomycosis: Vori, then Itra (in 1); Coccidioidomycosis: Vori, then Itra (in 1); Histoplasmosis: Vori, then Flu (in 1), Vori, then Itra (in 1), Itra
then Flu then Vori (in 1), Itra then Vori then Posa (in 1).
3Coccidioidomycosis: Flu then Vori then AmB (in 1); Histoplasmosis: Itra then AmB (in 3).
4Diagnosis made after death.
AmB, amphotericin B; Itra, itraconazole; Flu, fluconazole; Vori, voriconazole; Posa, posaconazole.
Table 6
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surveillance period, and the 1-year cumulative inci-
dence for histoplasmosis was 0.1%. The onset of
infection ranged from immediately post transplantation
to 11 years post transplantation, indicating that clini-
cians must include endemic mycoses in their differen-
tial diagnoses even many years after transplantation. A
bimodal distribution was seen, with 40% of cases
occurring within the first 6 months after transplanta-
tion when immunosuppression was greatest, and 34% of
infections occurring >2 years post transplantation. This
bimodal distribution has been noted previously in
smaller and single-center series of endemic mycoses
following organ transplantation, although some reports
showed a greater rate of infections occurring earlier
after transplantation than what we observed (5, 7–10).
Among HCT recipients in the Incidence Cohort, only 3
(0.02%) developed histoplasmosis. The reasons for this
low incidence are not known, but the rarity of endemic
mycoses among HCT recipients has been noted previ-
ously (1, 11, 12). Perhaps it is because these patients
are not likely to be engaged in outdoor activities before
engraftment or when undergoing intensive immuno-
suppression for GVHD, and they are usually on
antifungal prophylaxis during these periods. In addi-
tion, immune reconstitution occurs by 6 months in
many HCT recipients, in contrast with SOT recipients
who generally remain on continuing immunosuppres-
sion for years. This low rate also suggests infrequent
reactivation infection in this population, as described in
a prior retrospective review of allogeneic HCT recipi-
ents from an endemic area (12).
Rejection did not appear to have a major role in
development of endemic mycoses in SOT recipients.
Other investigators also have reported similar findings
with histoplasmosis and blastomycosis (5, 7–9), but
rejection has been associated with a higher risk of
development of coccidioidomycosis (13). The role of
rejection as a risk factor for endemic fungal infections
differs greatly from that noted for invasive mold
infections, such as fusariosis, mucormycosis, and sce-
dosporiosis, in the TRANSNET cohort (4).
The geographic distribution of cases was similar to
the areas of endemicity for each of the 3 mycoses.
However, in 7 cases, the infection was reported from a
transplant center outside those areas. Four of these
patients had lived in or traveled to, before or after
receiving the transplant, an area endemic for the
infecting fungus. Thus, obtaining a precise travel
history is essential in evaluating the etiology of post-
transplant infections.
Three patients were documented to have received
organs that contained either Coccidioides species or
H. capsulatum. Blastomycosis was not documented as
a donor-derived infection in this series nor in other
previous reports (5, 8, 10). Donor-derived fungal
infections have been identified most often among
recipients of kidney transplants, but also have been
reported in recipients of other organs (6, 7, 10, 13–19).
Most recipients who receive an organ containing an
endemic fungus develop manifestations of infection
within several weeks post transplantation. One patient
in the current study received a donor liver that
contained organisms thought to be H. capsulatum;
with immediate therapy with an azole, she never
developed active histoplasmosis. This case is similar
to those of 4 patients from the Cleveland Clinic who
received donor lungs with H. capsulatum and who did
well post transplantation with itraconazole treatment
(7). It is possible that additional donor-derived infec-
tions occurred among the 40% of patients who mani-
fested infection within the first 6 months after
transplantation. However, we do not have data on the
donors or other transplant recipients who had received
organs from the same donors.
Not surprisingly, histoplasmosis was manifested in
three-quarters of patients as disseminated infection,
with or without documented pulmonary involvement.
The tendency for dissemination has also been reported
previously in other series of histoplasmosis in trans-
plant recipients (5, 7, 9). Widespread dissemination was
evidenced by the fact that more than half of the patients
had H. capsulatum isolated from blood cultures.
The lungs were the primary site of infection among
patients who had blastomycosis; those who did have
dissemination had localized disease. The limited num-
ber of cases of disseminated blastomycosis among
transplant recipients was noted in a prior report (5).
Although the 2 patients who received donor organs
containing Coccidioides species had widely dissemi-
nated infection, most of the other patients, including
the 2 HCT recipients, had more localized coccidioido-
mycosis. Four had pulmonary infection only, and 3 had
pulmonary involvement with dissemination docu-
mented only to skin or osteoarticular structures. In
contrast, other series from endemic areas for coccid-
ioidomycosis found a higher frequency of disseminated
disease among SOT recipients (13, 20). Those reports
that consist of greater numbers of patients likely, reflect
more accurately the types of disease caused by Coccid-
ioides species in the transplant population (13).
Treatment was determined by the practices at indi-
vidual transplant centers. Most patients were treated in
accordance with what later became the standard of
therapy, as detailed in the Infectious Diseases Society
of America guidelines for the respective infections
(21–23). Several findings are notable. Among patients
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who were treated with an AmB formulation, only 9%
received conventional AmB (deoxycholate formulation)
and 91% received a lipid formulation, reflecting
increased use of less toxic formulations and acceptance
of the evidence in AIDS patients that liposomal AmB is
more efficacious than the deoxycholate formulation for
treating disseminated histoplasmosis (24). The higher
death rate among those patients who received AmB
only likely reflects the severity of infection at
presentation.
Itraconazole is the agent recommended for step-
down therapy following AmB, and for initial therapy of
mild-to-moderate histoplasmosis and blastomycosis
(21, 22). However, more patients who had blastomyco-
sis were treated with voriconazole than with itracona-
zole. Some clinicians chose to use voriconazole rather
than itraconazole because it achieves higher cerebro-
spinal fluid levels and is better absorbed. However,
clinical experience treating blastomycosis and histo-
plasmosis with voriconazole is limited compared to that
with itraconazole, and both success and failure have
been noted (8, 25).
This study has several limitations. First, the institu-
tions in our study were not equally distributed across all
geographic areas in which the endemic mycoses occur.
Fewer sites were located in areas in which coccidioi-
domycosis is endemic than in sites in which histoplas-
mosis and blastomycosis are endemic. Thus, the low
number of cases of coccidioidomycosis is probably not
an accurate representation of the rate of occurrence of
infection with this organism in the transplant popula-
tion. Second, to establish more firmly whether infection
was donor-derived, it is essential to have information on
donors and other transplant recipients who shared
organs from the same donor. These data were not
accessible to us and have rarely been available in prior
studies of transplant-related endemic mycoses. Third,
detailed data on diagnostic testing were not collected in
this surveillance study. Future studies that collect data
on the height and duration of antigenemia and anti-
genuria, and how those tests influence the accuracy
and rapidity of diagnosis of histoplasmosis, will provide
useful information for the clinician.
Our large multicenter study provides comprehensive
surveillance data defining the incidence of endemic
mycoses among SOT and HCT recipients in the United
States. We found that overall rates of infection with the
endemic mycoses in the transplant population are low,
but the risk continues for many years post transplan-
tation. The response to therapy of these infections is
excellent, but physicians must be vigilant in order to
establish the diagnosis early and initiate appropriate
antifungal treatment in this vulnerable population.
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